NCT00034255View on ClinicalTrials.gov

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 31, 2001

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

INGAP Peptide

Trial Locations (4)

20003

MedStar Research Institute - Clinical Research Center, Washington D.C.

27713

UNC Diabetes, Endocrinology, Metabolism Clinic, Durham

78284

Texas Diabetes Institute, San Antonio

92161

VASDHS Medical Center, San Diego

Sponsors
All Listed Sponsors
lead

GMP Endotherapeutics

INDUSTRY

NCT00034255 - Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients | Biotech Hunter | Biotech Hunter